Mylan Argues For High Court Review On If ANDA Subjects Filers To Personal Jurisdiction
WASHINGTON, D.C. — Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) argue in a Dec. 7 reply brief that drug companies failed to show why the U.S. Supreme Court should not...To view the full article, register now.
Already a subscriber? Click here to view full article